Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy

“…[24][25][26] In addition to the association of PCV phenotypes, several investigators reported the relationship between ARMS2 A69S and treatment response for PCV including PDT monotherapy, intravitreal anti-VEGF treatment monotherapy and combination therapy. [18,22,[27][28][29][30][31] Most studies focused on visual outcomes or recurrence after treatment and demonstrated that at-risk allele homozygosity (TT genotype) at A69S of ARMS2 were more likely to recur compared with other genotypes. In addition to revealing that recurrence was more frequently seen in risk allele of ARMS2 A69S dependent fashion, multiple regression analysis revealed that time to recurrence extended by 15.5 months when G allele (non-risk allele) of ARMS2 A69S increased by one allele.…”

Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis

“…Furthermore, in order to differentiate PCV patients among exudative AMD patients, we checked, by hand, the 130 research articles passing the filtering criteria, and we selected only those studying the genetic variants affecting the response to anti-VEGF drugs in PCV patients exclusively (Figure 1). Finally, six scientific articles were identified as publications exploring genetic variants affecting anti-VEGF drug response in PCV patients [35][36][37][38][39][40]; none of these manuscripts obtained a NOS score under five points, and no evidence of publication bias was found after Harbord′s test. Altogether, these articles investigated 11 different variants in nine genes (Table 2), all MAFs were higher than 0.01, and all of them were in Asian populations (Korea or Japan) treated with anti-VEGF drugs (ranibizumab, bevacizumab, and aflibercept).…”

“…In greater detail, three articles included patients treated with PDT in addition to anti-VEGF drugs (36,39,40), and three articles included nAMD patients in addition to PCV patients [37,38]. Furthermore, Kawashima Y et al [37] recruited refractory-to-ranibizumab patients treated with aflibercept and did not provide results that differentiated between PCV and nAMD patients.…”

“…Additionally, regarding the second research article by Hata et al [39], in PCV patients treated only with ranibizumab and PDT, they found the T risk allele in ARMS2 A69S (rs10490924) to be related to higher rates of recurrence and a reduction of visual acuity between 12 and 24 months of treatment. Finally, Nakai et al [40] concluded, among PCV patients, that G allele in ARMS2 A69S (rs10490924) is likely associated with a lower chance of retreatment after aflibercept and PDT. Finally, six scientific articles were identified as publications exploring genetic variants affecting anti-VEGF drug response in PCV patients [35][36][37][38][39][40]; none of these manuscripts obtained a NOS score under five points, and no evidence of publication bias was found after Harbord s test.…”

“…Additionally, regarding the second research article by Hata et al [39], in PCV patients treated only with ranibizumab and PDT, they found the T risk allele in ARMS2 A69S (rs10490924) to be related to higher rates of recurrence and a reduction of visual acuity between 12 and 24 months of treatment. Finally, Nakai et al [40] concluded, among PCV patients, that G allele in ARMS2 A69S (rs10490924) is likely associated with a lower chance of retreatment after aflibercept and PDT.…”